Skip to main content

Table 1 Clinical characteristics of patients with uveitis according to final diagnosis

From: Coinfections and differential diagnosis in immunocompetent patients with uveitis of infectious origin

Characteristics of patients Median (range) or number/total (percent) in COT patients (n = 22) Median (range) or number/total (percent) in UOT patients (n = 16) Median (range) or number/total in OU patients (n = 23) Median (range) or number/total in COINF patients (n = 5) p
Age 37,5 (13–70) 30 (19–74) 34 (17–79) 50,2 (16–79) 0,523
Gender Female 10/22 (45,5%) 6/16 (37,5%) 14/23 (60,9%) 2/5 (40% 0,492
Localization of uveitis (anterior, posterior and panuveitis) 0/22 (0%) anterior
12/22 (54,5%) posterior 10/22 (45,5%) panuveitis
1/16 (6,3%) anterior
14/16 (87,5%)% posterior 1/16 (6,3%) panuveitis
5/23 (21,7%) anterior
9/23 (39,1%) posterior 9/23 (39,1%) panuveitis
0/5 (0%) anterior
1/5 (20%) posterior 4/5 (80%) panuveitis
0,004
Bilateral involvement 3/22 (13,6%) 2/16 (12,5%) 7/23 (30,4%) 2/5 (40%) 0,351
Cataract 6/22 (27,2%) 4/16 (25%) 8/23 (34,7%) 1/5 (20%) 0,655
Papillitis 3/22 (13,6%) 1/16 (6,3%) 4/23 (17,4%) 1/5 (20%) 0,539
Total number of scars (both eyes) 2,5 (1–11) 2 (1–18) 1,5 (1–4) 2,5 (2–3) 0,800
Number of inflammatory cells in vitreous humor 2 (0–4) 0,5 (0–4) 1 (0–4) 2 (0–4) 0,403
Median size of scars in disk diameters 1,53 (1–6) 1 (1–4) 0,9 (1–3) 1,3 (1–2) 0,157
Median number of recurrences episodes 1,81 (0–10) 1 (0–4) 1,52 (0–10) 0,6 (0–2) 0,658
Number (%) of IgM serological test positive for virus (EBV, CMV, HVS1, HVS2) 2/22 (9%) 2/16 (18,8%) 5/23 (21,7%) 0/5 (0%) 0,716
Number of patients with intraocular pressure > 20 mmHg 4/22 (18,2%) 1/16 (6,3%) 2/23 (8,7%) 1/5 (12,5%) 0,236
Number of patients (%) with change of treatment after diagnosis 3/22 (13,6%) 1/16 (6,3%) 13/23 (56.5%) 3/5 (60%) 0,002
Significant clinical improvement after treatment change 3/3 (100%) 1/1 (100%) 12/13 (92,3%) 3/3 (100%)
Significant clinical improvement after 6 months of treatment (regardless of whether there was change or continuation) 21/22 (95.4%) 14/16 (87.5%) 20/23 (86.95%) 4/5 (80%)
IgG for Toxoplasmosis: qualitative 22/22 (100%) 16/16 (100%) 3/23 (13%) 5/5 (100%)
IgM for Toxoplasmosis: qualitative 3/22 (13.6%) 0/16 (0%) 1/23 (4.34%) 0/5 (0%)
IgM for EBV: qualitative 2/22 (9%) 2/16 (33.3%) 3/23 (13%) 0/5 (0%)
IgM for CMV: qualitative 0/22 (0%) 0/16 (0%) 0/23 (0%) 0/5 (0%)
IgM for HSV-1: qualitative 0/22 (0%) 0/16 (0%) 2/23 (8.6%) 0/5 (0%)
IgM for HSV-2: qualitative 0/22 (0%) 0/16 (0%) 0/23 (0%) 0/5 (0%)
  1. COINF Co-infection, COT Confirmed ocular toxoplasmosis, OU Other uveitis, UOT Undetermined ocular toxoplasmosis
  2. *statistically significant difference (p< 0,05)